Results 21 to 30 of about 139,370 (300)

Outcomes of Severe Sepsis and Septic Shock Patients on Chronic Antiplatelet Treatment: A Historical Cohort Study

Critical Care Research and Practice, 2013
Background. Sepsis is characterized by dysfunctional activation of platelets, and antiplatelet therapy could improve the outcomes of septic patients. Methods.
Juan C. Valerio-Rojas, Insara J. Jaffer, Daryl J. Kor, Ognjen Gajic, Rodrigo Cartin-Ceba   +4 more
doaj   +1 more source

Stroke of antiplatelet and anticoagulant therapy in patients with coronary artery disease: a meta-analysis of randomized controlled trials

BMC Cardiovascular Disorders, 2021
Background We performed a meta-analysis sought to investigate the risk of stroke with antiplatelet and anticoagulant therapies among patients with coronary artery disease (CAD).
Qiao Yu Shao, Zhi Jian Wang, Xiao Teng Ma, Xu Ze Lin, Liu Pan, Yu Jie Zhou   +5 more
doaj   +1 more source

rLOAD: does sex mediate the effect of acute antiplatelet loading on stroke outcome. [PDF]

, 2014
BackgroundBiologic sex can influence response to pharmacologic therapy. The purpose of this proof-of-concept study was to evaluate the medicating effects of estrogen in the efficacy of acute antiplatelet loading therapy on stroke outcome in the rabbit ...
Compton, M Peggy, Eastwood, Jo-Ann, Gylys, Karen, Meyer, Dawn M, Zivin, Justin A   +4 more
core   +3 more sources

Factors associated with intracerebral hemorrhage after thrombolytic therapy for ischemic stroke pooled analysis of placebo data from the Stroke-Acute Ischemic NXY Treatment (SAINT) I and SAINT II trials [PDF]

, 2009
<p><b>Background and Purpose:</b> A number of factors have been associated with postthrombolysis intracerebral hemorrhage, but these have varied across studies.</p> <p><b>Methods:</b> We examined patients with
Cucchiara, B., Demchuk, A., Kasner, S.E., Lees, K.R., Levine, S.R., Lyden, P., Messe, S.R., Sansing, L., Tanne, D.   +8 more
core   +1 more source

Impact of Modifiable Bleeding Risk Factors on Major Bleeding in Patients With Atrial Fibrillation Anticoagulated With Rivaroxaban. [PDF]

, 2020
Background Reducing major bleeding events is a challenge when managing anticoagulation in patients with atrial fibrillation. This study evaluated the impact of modifiable and nonmodifiable bleeding risk factors in patients with atrial fibrillation ...
Amarenco, P, Camm, AJ, Haas, S, Hess, S, Kirchhof, P, Lambelet, M, Turpie, AGG, van Eickels, M, XANTUS Investigators*   +8 more
core   +2 more sources

The CLEAR (Considering Leading Experts’ Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention

CVIR Endovascular, 2019
Background Antiplatelet and anticoagulant therapy are commonly used before, during and after peripheral arterial endovascular intervention. This survey aimed to establish antiplatelet and anticoagulant choice for peripheral arterial endovascular ...
Kitty H. F. Wong, Dave C. Bosanquet, Graeme K. Ambler, Mahim I. Qureshi, Robert J. Hinchliffe, Christopher P. Twine, CLEAR survey collaborators   +6 more
doaj   +1 more source

The efficacy and safety of CYP2C19 genotype-guided antiplatelet therapy compared with conventional antiplatelet therapy in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: A meta-analysis of randomized controlled trials

Platelets, 2020
Cytochrome P450 (CYP) 2C19 genotype is closely associated with the metabolism and efficacy of clopidogrel, thereby having an important impact on clinical outcomes of patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary ...
Si-Qi Lyu, Yan-Min Yang, Jun Zhu, Juan Wang, Shuang Wu, Han Zhang, Xing-Hui Shao, Jia-Meng Ren   +7 more
doaj   +1 more source

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, George A. Stouffer, Craig R. Lee, Craig R. Lee   +5 more
doaj   +1 more source

Is clopidogrel better than aspirin following breakthrough strokes while on aspirin? A retrospective cohort study. [PDF]

, 2014
ObjectiveThere is insufficient evidence on which to base a recommendation for optimal antiplatelet therapy following a stroke while on aspirin. The objective was to compare clopidogrel initiation vs aspirin reinitiation for vascular risk reduction among ...
Chang, Ku-Chou, Lee, Hsuei-Chen, Lee, Jiann-Der, Lee, Meng, Lee, Tsong-Hai, Ovbiagele, Bruce, Rao, Neal M, Saver, Jeffrey L, Wang, Hui-Hsuan, Wu, Chih-Ying, Wu, Yi-Ling   +10 more
core   +1 more source

Outcomes Associated With Oral Anticoagulants Plus Antiplatelets in Patients With Newly Diagnosed Atrial Fibrillation. [PDF]

, 2020
Importance: Patients with nonvalvular atrial fibrillation at risk of stroke should receive oral anticoagulants (OAC). However, approximately 1 in 8 patients in the Global Anticoagulant Registry in the Field (GARFIELD-AF) registry are treated with ...
Bassand, J-P, Camm, AJ, Dabrowski, E, Fitzmaurice, DA, Fox, KAA, GARFIELD-AF Investigators, Gersh, BJ, Gibbs, L, Goldhaber, SZ, Goto, S, Haas, S, Kakkar, AK, Luo, K, Misselwitz, F, Pieper, KS, Turpie, AGG, Velentgas, P, Verheugt, FWA   +17 more
core   +2 more sources